WuXi Healthcare Ventures

WuXi Healthcare Ventures was a Chinese investment firm focused on supporting life sciences companies in the development of transformative therapies. Based in Cambridge, Massachusetts, with an additional office in Shanghai, China, the firm specialized in investments in life science, therapeutic, platform technology, and diagnostic companies, with particular emphasis on opportunities in China and the United States. In May 2017, WuXi Healthcare Ventures merged with Frontline BioVentures, resulting in the formation of a new entity called 6 Dimensions Capital.

Edward Hu

Founding Partner

39 past transactions

Adlai Nortye

Series D in 2021
Adlai Nortye Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the research and development of innovative oncology therapies. Founded in 2004 and formerly known as Sinopep Pharmaceutical Inc., the company focuses on developing cancer treatments and addressing metabolic diseases. Adlai Nortye operates R&D and clinical operation centers in both China and the United States, emphasizing its global approach to drug development. The company has established a robust pipeline featuring over ten drug candidates, including those in various stages of clinical and preclinical development, such as buparlisib, palupiprant, and AN4005. Through collaborations and internal discoveries, Adlai Nortye seeks to advance its goal of providing effective treatment options for patients with a wide range of tumor types.

Zenas BioPharma

Series A in 2021
Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

LifeMine Therapeutics

Series B in 2021
LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

XW Laboratories

Series C in 2020
XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the development of innovative treatments for neurological disorders. Founded in 2014, the company has established three distinct research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of novel drug candidates while minimizing development costs and time. The company is committed to creating medications that enhance patient compliance and reduce toxicity. Additionally, XW Laboratories is advancing its capabilities in immunoneurology through a mitochondria-targeting platform. While primarily focused on the Chinese market, the company also engages in collaborations to reach foreign markets, aiming to transform the quality of life for patients suffering from neurological conditions.

Halda Therapeutics

Series A in 2019
Halda Therapeutics is a research-stage drug discovery company dedicated to developing next-generation precision medicine. The company employs a unique therapeutic modality that serves as a platform for addressing various disease states. By focusing on the discovery of novel therapies that modify disease-causing pathways, Halda Therapeutics aims to enable healthcare providers to offer more targeted treatments for their patients. Through its innovative approach, the company seeks to advance the field of precision medicine and improve patient outcomes.

Antengene

Series B in 2019
Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.

Refuge Biotechnologies

Series B in 2018
Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.

Unity Biotechnology

Series C in 2018
Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing age-related diseases. The company specializes in clearing senescent cells through the creation of senolytic medicines, which specifically target vulnerabilities unique to these cells while sparing healthy ones. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal conditions like osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is developing treatments for various conditions related to aging, including pulmonary and neurological disorders, as well as kidney and liver diseases. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was previously known as Forge, Inc. before changing its name in 2015.

IDEAYA Biosciences

Series B in 2018
IDEAYA Biosciences, Inc., established in 2015 and headquartered in South San Francisco, California, specializes in oncology-focused precision medicine. The company discovers and develops targeted therapeutics for patient populations selected through molecular diagnostics. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently in Phase 1/2 clinical trials for genetically-defined cancers with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting MAT2A, Pol-theta, PARG, and WRN in various solid tumors. The company collaborates with institutions like Cancer Research UK and Pfizer Inc., and has partnerships with industry leaders such as GlaxoSmithKline plc.

Medeor Therapeutics

Series B in 2017
Medeor Therapeutics, Inc. is a biotechnology company focused on researching, developing, and commercializing innovative cellular immunotherapies aimed at enhancing outcomes for organ transplant recipients. Based in San Mateo, California, Medeor Therapeutics has developed a specialized immunotherapy product for kidney transplant recipients known as MDR-10X. The company's cellular immunotherapies target organ transplant immune tolerance and immuno-oncology, providing healthcare providers with advanced techniques to preserve or improve kidney function and mitigate the risk of graft rejection more effectively than traditional immunosuppression therapies. Incorporated in 2012, Medeor Therapeutics is dedicated to transforming transplant outcomes through personalized treatment strategies.

XW Laboratories

Series B in 2017
XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the development of innovative treatments for neurological disorders. Founded in 2014, the company has established three distinct research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of novel drug candidates while minimizing development costs and time. The company is committed to creating medications that enhance patient compliance and reduce toxicity. Additionally, XW Laboratories is advancing its capabilities in immunoneurology through a mitochondria-targeting platform. While primarily focused on the Chinese market, the company also engages in collaborations to reach foreign markets, aiming to transform the quality of life for patients suffering from neurological conditions.

LifeMine Therapeutics

Series A in 2017
LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Vivace Therapeutics

Series B in 2017
Vivace Therapeutics, Inc. is a biotechnology company focused on the discovery and development of small molecule therapies aimed at treating cancer. Founded in 2014 and located in the San Francisco Bay Area, the company specializes in targeting the Hippo pathway, which plays a critical role in regulating tissue regeneration and organ size. Vivace Therapeutics employs an innovative approach by leveraging research from leading academic institutions to develop novel therapeutics that can be used independently or in combination with existing treatments. The company is committed to advancing promising drug candidates and therapeutic technologies to address the unmet needs of cancer patients, driven by a mission to improve patient outcomes and quality of life.

Ivenix

Venture Round in 2017
Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, specializing in the development of advanced intravenous (IV) infusion systems. Founded in 2001 and originally known as Fluidnet Corporation, Ivenix offers a next-generation infusion management platform that utilizes pneumatic technology to enhance the accuracy of fluid delivery. This innovative system is designed to measure and control flow regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. Additionally, the platform manages patient infusion data and integrates seamlessly with clinical information systems, ensuring precise and continuous infusion delivery in hospital settings. Ivenix aims to revolutionize infusion therapy worldwide by combining state-of-the-art information technology with user-friendly design, thereby improving patient care and safety.

Forerunner Medical

Series B in 2017
Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of innovative medical devices aimed at minimally invasive treatments. The company focuses on creating low-temperature plasma radio-frequency generators and electrodes specifically designed for sports medicine and tumor treatment. By leveraging extensive domestic clinical data and advanced technology, Forerunner Medical aims to meet both domestic and global healthcare needs. The organization emphasizes the quality and safety of its products, ensuring high performance, aesthetic appeal, and user convenience. Its commitment to excellence is reflected in its state-of-the-art production equipment and professional expertise, which contribute to its competitive advantage in the medical device industry.

TenNor Therapeutics

Series B in 2016
TenNor Therapeutics is a clinical-stage product development company dedicated to addressing unmet medical needs in the field of infectious diseases. The company utilizes a dual-acting drug discovery platform to advance a portfolio of innovative products currently in various stages of preclinical and clinical development. TenNor focuses on developing new treatments for complications arising from Helicobacter pylori infections, prosthetic joint infections, and multidrug-resistant Gram-negative infections, among other significant infectious diseases. Additionally, the company's multi-targeting approach aims to offer solutions for gastrointestinal tract infections, medical device infections, and bacterial dysbiosis, thereby providing new therapeutic options for conditions that lack effective treatments.

Nutrinia

Series D in 2016
Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals to address rare gastrointestinal conditions in infants. Based in Ramat-Gan, Israel, the company has created oral formulations of insulin designed to enhance gut adaptation and rehabilitation in premature infants and children. Its key clinical programs include NTRA-2112, which aims to reduce enteral nutrition intolerance, promote growth velocity and weight gain, and decrease the length of stay in neonatal intensive care units. Another significant product, NTRA-9620, targets short bowel syndrome by improving bowel adaptation post-resection, facilitating enteral nutrition, and minimizing the reliance on parenteral nutrition. Founded in 2003, Nutrinia is committed to improving the health outcomes of vulnerable populations through innovative scientific solutions.

Avelas Biosciences

Series C in 2016
Avelas Biosciences is focused on advancing cancer surgery through innovative intraoperative imaging technology. The company has developed a proprietary platform that utilizes activatable cell-penetrating peptides to provide real-time diagnosis of metastatic nodes during surgical procedures. This technology enables oncologic surgeons to create a luminous map of the surgical area, improving their ability to identify and remove cancerous tissue effectively. By enhancing surgical precision, Avelas Biosciences aims to reduce the need for repeat surgeries and ultimately improve patient outcomes, establishing a new standard of care in oncological surgery.

CStone Pharmaceuticals

Series A in 2016
CStone Pharmaceuticals is a clinical-stage biotechnology company based in Shanghai, China, focused on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment globally. Founded in 2015, the company has established a robust product pipeline that includes late-stage clinical candidates such as CS1001 and CS1003, which are monoclonal antibodies targeting programmed death ligands and receptors. Other notable products include ivosidenib, avapritinib, and Pralsetinib, which are designed to treat various cancers. CStone also develops additional candidates like CS1002, CS3002, CS3003, and Fisogatinib for solid tumors and liver cancer, respectively. The company has entered into strategic collaborations, including a licensing agreement with Numab Therapeutics AG for a tri-specific antibody and a clinical partnership with Bayer HealthCare to evaluate CS1001 in combination with other treatments. CStone Pharmaceuticals aims to meet the pressing medical needs of cancer patients through innovative therapies and has assembled a management team with extensive experience in drug development and commercialization.

IDEAYA Biosciences

Series A in 2016
IDEAYA Biosciences, Inc., established in 2015 and headquartered in South San Francisco, California, specializes in oncology-focused precision medicine. The company discovers and develops targeted therapeutics for patient populations selected through molecular diagnostics. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently in Phase 1/2 clinical trials for genetically-defined cancers with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting MAT2A, Pol-theta, PARG, and WRN in various solid tumors. The company collaborates with institutions like Cancer Research UK and Pfizer Inc., and has partnerships with industry leaders such as GlaxoSmithKline plc.

Hua Medicine

Series C in 2016
Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

Adagene

Series B in 2016
Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. The company utilizes its proprietary Smart Antibody Technology to enhance the success rates of antibody development, significantly expedite the time to market, and lower the associated costs of creating therapeutic antibodies. Adagene is actively engaged in the research, development, and production of monoclonal antibody drugs aimed at treating various types of cancer. Its innovative platform is designed to generate therapeutic antibody candidates that exhibit functional epitopes and species cross-reactivity, underscoring the potential impact of its immunotherapy pipeline in addressing cancer treatment challenges.

Forerunner Medical

Series A in 2016
Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of innovative medical devices aimed at minimally invasive treatments. The company focuses on creating low-temperature plasma radio-frequency generators and electrodes specifically designed for sports medicine and tumor treatment. By leveraging extensive domestic clinical data and advanced technology, Forerunner Medical aims to meet both domestic and global healthcare needs. The organization emphasizes the quality and safety of its products, ensuring high performance, aesthetic appeal, and user convenience. Its commitment to excellence is reflected in its state-of-the-art production equipment and professional expertise, which contribute to its competitive advantage in the medical device industry.

Twist Bioscience

Series D in 2016
Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Syros Pharmaceuticals

Series C in 2016
Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Refuge Biotechnologies

Series A in 2016
Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.

AltheaDx

Series C in 2015
AltheaDx, Inc. is a molecular diagnostics company based in San Diego, California, specializing in pharmacogenetics. The company utilizes an algorithm-based bioinformatics platform and a portfolio of pharmacogenetic testing products to assist healthcare providers in identifying the most suitable medications and dosage guidelines tailored to patients' genetic profiles and existing prescriptions. AltheaDx's IDgenetix test facilitates personalized therapeutic decisions for patients with common clinical conditions, including cardiovascular disease and neuropsychiatric disorders. Additionally, the company offers research and development services that encompass molecular biomarker discovery, assay development, and clinical trial testing, aimed at supporting diagnostic development for pharmaceutical, biotech, and medical device companies. AltheaDx serves a diverse range of clients, including long-term care facilities, government organizations, integrated delivery networks, and physicians. Founded in 1998, AltheaDx has established itself as a key player in the field of personalized medicine.

Lumo Bodytech

Series B in 2015
Lumo Bodytech, founded in 2011 and based in Mountain View, California, develops a technology platform that uses smart sensors and software to optimize human performance and address biomechanics through real-time tracking of body movement. The company offers products such as the Lumo Lift posture coach and activity tracker, and the Lumo Run sensor, which measures and coaches users on running form. Additionally, Lumo provides the Lumo MotionScience platform that delivers feedback on human movement. These products are sold online, through other online retailers in the United States, international distribution partners, and professional business retailers.

23andMe

Series E in 2015
23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Tunitas Therapeutics

Series A in 2015
Tunitas Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, focused on developing innovative protein therapeutics for allergy sufferers. Founded in 2007, the company specializes in creating genetically engineered fusion proteins, including its lead product, Epsi-gam, which combines human IgE and IgG1 components. These therapeutics aim to target and inhibit key pathways involved in allergic reactions, thereby disrupting the production of IgE, the antibody responsible for triggering allergic responses. Tunitas Therapeutics seeks to provide patients with effective treatment options for various IgE-mediated diseases, such as asthma and severe food allergies, through a regimen administered in their allergists’ offices. The company's mission is to significantly improve the quality of life for individuals suffering from serious allergic conditions.

Ivenix

Venture Round in 2015
Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, specializing in the development of advanced intravenous (IV) infusion systems. Founded in 2001 and originally known as Fluidnet Corporation, Ivenix offers a next-generation infusion management platform that utilizes pneumatic technology to enhance the accuracy of fluid delivery. This innovative system is designed to measure and control flow regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. Additionally, the platform manages patient infusion data and integrates seamlessly with clinical information systems, ensuring precise and continuous infusion delivery in hospital settings. Ivenix aims to revolutionize infusion therapy worldwide by combining state-of-the-art information technology with user-friendly design, thereby improving patient care and safety.

Hua Medicine

Series B in 2015
Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

Vivace Therapeutics

Series A in 2015
Vivace Therapeutics, Inc. is a biotechnology company focused on the discovery and development of small molecule therapies aimed at treating cancer. Founded in 2014 and located in the San Francisco Bay Area, the company specializes in targeting the Hippo pathway, which plays a critical role in regulating tissue regeneration and organ size. Vivace Therapeutics employs an innovative approach by leveraging research from leading academic institutions to develop novel therapeutics that can be used independently or in combination with existing treatments. The company is committed to advancing promising drug candidates and therapeutic technologies to address the unmet needs of cancer patients, driven by a mission to improve patient outcomes and quality of life.

Unity Biotechnology

Series A in 2015
Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing age-related diseases. The company specializes in clearing senescent cells through the creation of senolytic medicines, which specifically target vulnerabilities unique to these cells while sparing healthy ones. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal conditions like osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is developing treatments for various conditions related to aging, including pulmonary and neurological disorders, as well as kidney and liver diseases. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was previously known as Forge, Inc. before changing its name in 2015.

Adagene

Series A in 2014
Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. The company utilizes its proprietary Smart Antibody Technology to enhance the success rates of antibody development, significantly expedite the time to market, and lower the associated costs of creating therapeutic antibodies. Adagene is actively engaged in the research, development, and production of monoclonal antibody drugs aimed at treating various types of cancer. Its innovative platform is designed to generate therapeutic antibody candidates that exhibit functional epitopes and species cross-reactivity, underscoring the potential impact of its immunotherapy pipeline in addressing cancer treatment challenges.

Syros Pharmaceuticals

Series B in 2014
Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Avelas Biosciences

Series B in 2014
Avelas Biosciences is focused on advancing cancer surgery through innovative intraoperative imaging technology. The company has developed a proprietary platform that utilizes activatable cell-penetrating peptides to provide real-time diagnosis of metastatic nodes during surgical procedures. This technology enables oncologic surgeons to create a luminous map of the surgical area, improving their ability to identify and remove cancerous tissue effectively. By enhancing surgical precision, Avelas Biosciences aims to reduce the need for repeat surgeries and ultimately improve patient outcomes, establishing a new standard of care in oncological surgery.

IMPACT Therapeutics

Series A in 2014
IMPACT Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009 and based in Shanghai, China, the company focuses on creating targeted anti-cancer treatments utilizing synthetic lethality. IMPACT Therapeutics is actively engaged in several research and development projects, including a PARP inhibitor, a Wee1 inhibitor, and various novel agents targeting DNA damage response mechanisms and the Hedgehog signaling pathway. Through its commitment to advancing treatment options, IMPACT Therapeutics aims to provide patients with effective and targeted anti-cancer therapies.

Hua Medicine

Series A in 2011
Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.